ERS Genomics Limited ('ERS'), the CRISPR licensing company, today announced the launch of its Early Access Express License, a ...
Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that management will be parti ...
WISN 12 News on MSN
FDA proposes new system for approving customized drugs and therapies for rare diseases
Federal health officials on Monday laid out a proposal to spur development of customized treatments for patients with hard-to ...
Learn more about the cutting-edge technology that enables 3D printing inside living cells and what that means for the ...
The UK Rare Diseases Framework, led by the Department of Health and Social Care, also helps drive collaborative progress ...
"Gene editing takes centre stage in FDA’s new rare disease approval pathway" was originally created and published by ...
Through an AI-enabled platform, the partnership between two non-profit groups seeks to bring overlooked cell and gene ...
The FDA released a much-anticipated draft guidance on how makers of rare disease genetic medicines can leverage a platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results